To access the full text documents, please follow this link: http://hdl.handle.net/2445/147807
dc.contributor.author | Castella, Maria |
---|---|
dc.contributor.author | Boronat, Anna |
dc.contributor.author | Martín Ibáñez, Raquel |
dc.contributor.author | Rodríguez, Vanina |
dc.contributor.author | Suñé, Guillermo |
dc.contributor.author | Caballero, Miguel |
dc.contributor.author | Marzal, Berta |
dc.contributor.author | Pérez-Amill, Lorena |
dc.contributor.author | Martín-Antonio, Beatriz |
dc.contributor.author | Castaño, Julio |
dc.contributor.author | Bueno, Clara |
dc.contributor.author | Balagué, Olga |
dc.contributor.author | González-Navarro, Europa Azucena |
dc.contributor.author | Serra Pagès, Carles |
dc.contributor.author | Engel Rocamora, Pablo |
dc.contributor.author | Vilella, Ramon |
dc.contributor.author | Benítez-Ribas, Daniel |
dc.contributor.author | Ortiz-Maldonado, Valentín |
dc.contributor.author | Cid Vidal, Joan |
dc.contributor.author | Tabera, Jaime |
dc.contributor.author | Canals i Coll, Josep M. |
dc.contributor.author | Lozano, Miquel |
dc.contributor.author | Baumann, Tycho |
dc.contributor.author | Vilarrodona, Anna |
dc.contributor.author | Trias, Esteve |
dc.contributor.author | Campo Güerri, Elias |
dc.contributor.author | Menéndez Buján, Pablo |
dc.contributor.author | Urbano Ispizua, Álvaro |
dc.contributor.author | Yagüe, Jordi |
dc.contributor.author | Pérez Galán, Patricia |
dc.contributor.author | Rives, Susana |
dc.contributor.author | Delgado, Julio (Delgado González) |
dc.contributor.author | Juan, Manel |
dc.date | 2020-01-14T16:39:59Z |
dc.date | 2020-01-14T16:39:59Z |
dc.date | 2018-12-06 |
dc.date | 2020-01-14T16:40:00Z |
dc.identifier | 2329-0501 |
dc.identifier | 684889 |
dc.identifier | 4148378 |
dc.identifier.uri | http://hdl.handle.net/2445/147807 |
dc.description | Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19 based on our own anti-CD19 antibody (A3B1), followed by CD8 hinge and transmembrane region, 4-1BB- and CD3z-signaling domains. We show that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells in vitro, inducing secretion of pro-inflammatory cytokines and CAR T cell proliferation. In vivo, A3B1 CAR T cells are able to fully control disease progression in an NOD.Cg-Prkdcscid Il2rdtm1Wjl/SzJ (NSG) xenograph B-ALL mouse model. Based on the pre-clinical data, we conclude that our CART19 is clearly functional against CD19+ cells, to a level similar to other CAR19s currently being used in the clinic. Concurrently, we describe the implementation of our CAR T cell production system, using lentiviral vector and CliniMACS Prodigy, within a medium-sized academic institution. The results of the validation phase show our system is robust and reproducible, while maintaining a low cost that is affordable for academic institutions. Our model can serve as a paradigm for similar institutions, and it may help to make CAR T cell treatment available to all patients. |
dc.format | 11 p. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | Cell Press |
dc.relation | Reproducció del document publicat a: https://doi.org/10.1016/j.omtm.2018.11.010 |
dc.relation | Molecular Therapy-Methods & Clinical Development, 2018, vol. 12, p. 134-144 |
dc.relation | https://doi.org/10.1016/j.omtm.2018.11.010 |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/646903/EU//INFANTLEUKEMIA |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/811220/EU//IT4B-ALL |
dc.rights | cc-by (c) Castella, Maria et al., 2018 |
dc.rights | http://creativecommons.org/licenses/by/3.0/es |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Immunoteràpia |
dc.subject | Leucèmia |
dc.subject | Limfomes |
dc.subject | Cèl·lules T |
dc.subject | Immunotheraphy |
dc.subject | Leukemia |
dc.subject | Lymphomas |
dc.subject | T cells |
dc.title | Development of a novel anti-CD19 chimeric antigen receptor: A paradigm for an affordable CAR T cell production at academic institutions |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |